Paroxetine: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett (New page: In medicine, '''paroxetine''' is a second-generation antidepressant used for treating major depression. Its pharmacological action is a serotonin uptake inhibitor. Paroxet...) |
imported>Robert Badgett No edit summary |
||
| Line 1: | Line 1: | ||
In [[medicine]], '''paroxetine''' is a [[second-generation antidepressant]] used for treating [[major depression]]. Its pharmacological action is a [[serotonin uptake inhibitor]]. | In [[medicine]], '''paroxetine''' is a [[second-generation antidepressant]] used for treating [[major depression]]. Its pharmacological action is a [[serotonin uptake inhibitor]]. | ||
==Pharmacology== | |||
===Administration=== | |||
===Distribution=== | |||
===Metabolism=== | |||
Paroxetine is metabolized in the liver by [[cytochrome P-450 CYP2D6]]. | |||
===Excretion=== | |||
===Toxicity=== | |||
==Drug interactions== | |||
Paroxetine may increase death from [[breast cancer]] among women taking [[tamoxifen]] due to inhibiting metabolism of [[tamoxifen]] to its active metabolite by [[cytochrome P-450 CYP2D6]].<ref>{{Cite journal | doi = 10.1136/bmj.c693 | volume = 340 | issue = feb08_1 | pages = c693 | last = Kelly | first = Catherine M | coauthors = David N Juurlink, Tara Gomes, Minh Duong-Hua, Kathleen I Pritchard, Peter C Austin, Lawrence F Paszat | title = Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study | Paroxetine may increase death from [[breast cancer]] among women taking [[tamoxifen]] due to inhibiting metabolism of [[tamoxifen]] to its active metabolite by [[cytochrome P-450 CYP2D6]].<ref>{{Cite journal | doi = 10.1136/bmj.c693 | volume = 340 | issue = feb08_1 | pages = c693 | last = Kelly | first = Catherine M | coauthors = David N Juurlink, Tara Gomes, Minh Duong-Hua, Kathleen I Pritchard, Peter C Austin, Lawrence F Paszat | title = Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study | ||
| journal = BMJ | accessdate = 2010-02-10 | date = 2010-02-08 | url = http://www.bmj.com/cgi/content/abstract/340/feb08_1/c693 }}</ref> | | journal = BMJ | accessdate = 2010-02-10 | date = 2010-02-08 | url = http://www.bmj.com/cgi/content/abstract/340/feb08_1/c693 }}</ref> | ||
Revision as of 09:40, 10 February 2010
In medicine, paroxetine is a second-generation antidepressant used for treating major depression. Its pharmacological action is a serotonin uptake inhibitor.
Pharmacology
Administration
Distribution
Metabolism
Paroxetine is metabolized in the liver by cytochrome P-450 CYP2D6.
Excretion
Toxicity
Drug interactions
Paroxetine may increase death from breast cancer among women taking tamoxifen due to inhibiting metabolism of tamoxifen to its active metabolite by cytochrome P-450 CYP2D6.[1]
References
- ↑ Kelly, Catherine M; David N Juurlink, Tara Gomes, Minh Duong-Hua, Kathleen I Pritchard, Peter C Austin, Lawrence F Paszat (2010-02-08). "Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study". BMJ 340 (feb08_1): c693. DOI:10.1136/bmj.c693. Retrieved on 2010-02-10. Research Blogging.